Arcus Biosciences, Inc. (RCUS) Operating Margin
- Operating margin · 12 months: Value -852.63%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -852.63% | Operating income / revenue. Period ending 2026-06-30. $-486.00M ÷ $57.00M × 100 ≈ -852.63% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -486.00M USD | Operating Income (Loss) |
| Revenue | 57.00M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | |
| Research and development | 497.00M USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-486.00M | $57.00M | (m) | $497.00M | (m) | -852.63% |
| 2026-03-31 | $-398.00M | $32.00M | (m) | $523.00M | (m) | -1243.75% |
| 2025-12-31 | $-386.00M | $33.00M | (m) | $523.00M | (m) | -1169.70% |
| 2025-09-30 | $-375.00M | $45.00M | (m) | $503.00M | (m) | -833.33% |
| 2025-06-30 | $-338.00M | $46.00M | (m) | $485.00M | (m) | -734.78% |
| 2025-03-31 | $-436.00M | $49.00M | (m) | $461.00M | (m) | -889.80% |
| 2024-12-31 | $-330.00M | $51.00M | (m) | $448.00M | (m) | -647.06% |
| 2024-09-30 | $-318.00M | $263.00M | (m) | $440.00M | (m) | -120.91% |
| 2024-06-30 | $-293.00M | $247.00M | (m) | $399.00M | (m) | -118.62% |
| 2024-03-31 | $-270.00M | $237.00M | (m) | $368.00M | (m) | -113.92% |
| 2023-12-31 | $-340.00M | $117.00M | (m) | $340.00M | (m) | -290.60% |
| 2023-09-30 | $-323.00M | $120.00M | (m) | $327.00M | (m) | -269.17% |
| 2023-06-30 | $-313.00M | $121.00M | (m) | $322.00M | (m) | -258.68% |
| 2023-03-31 | $-299.00M | $119.00M | (m) | $308.00M | (m) | -251.26% |
| 2022-12-31 | $-280.00M | $112.00M | (m) | $288.00M | (m) | -250.00% |
| 2022-09-30 | $75.71M | $432.84M | (m) | $257.74M | (m) | 17.49% |
| 2022-06-30 | $66.97M | $408.72M | (m) | $252.31M | (m) | 16.38% |
| 2022-03-31 | $59.81M | $391.43M | (m) | $251.17M | (m) | 15.28% |
| 2021-12-31 | $54.25M | $382.88M | (m) | $256.35M | (m) | 14.17% |
| 2021-09-30 | $-279.03M | $37.87M | (m) | $255.12M | (m) | -736.81% |
| 2021-06-30 | $-199.34M | $92.94M | (m) | $235.67M | (m) | -214.49% |
| 2021-03-31 | $-168.58M | $85.23M | (m) | $202.59M | (m) | -197.80% |
| 2020-12-31 | $-124.23M | $77.52M | (m) | $159.35M | (m) | -160.27% |
| 2020-09-30 | $-89.75M | $77.78M | (m) | $131.32M | (m) | -115.39% |
| 2020-06-30 | $-114.55M | $15.00M | (m) | $96.76M | (m) | -763.68% |
| 2020-03-31 | $-98.34M | $15.00M | (m) | $86.07M | (m) | -655.57% |
| 2019-12-31 | $-88.71M | $15.00M | (m) | $78.48M | (m) | -591.39% |
| 2019-09-30 | $-84.67M | $6.81M | (m) | $69.23M | (m) | -1242.89% |
| 2019-06-30 | $-73.56M | $9.35M | (m) | $64.85M | (m) | -786.49% |
| 2019-03-31 | $-60.30M | $8.85M | (m) | $53.55M | (m) | -681.14% |
| 2018-12-31 | $-54.86M | $8.35M | (m) | $49.65M | (m) | -656.76% |
| 2018-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | $-53.44M | $1.41M | (m) | $47.22M | (m) | -3782.09% |
| 2017-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | $-18.18M | (m) | (m) | $14.25M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |